GlassScriptPhysician profile
Diana Lam
NPI 1790262392
$6,247.30
in general payments reported to CMS, 2019-2025
49 companies · $1,117 in 2025
The $1,117 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,579 · 2022: $43.27 · 2023: $98.70 · 2024: $2,410 · 2025: $1,117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,435.20 | 2021-2025 | |
| Lundbeck LLC | $441.29 | 2021-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $379.99 | 2021-2024 | Emgality, Amyvid, Kisunla |
| Biogen, INC. | $372.48 | 2021-2024 | Tysabri, Vumerity, Aduhelm |
| Novartis Pharmaceuticals Corporation | $288.89 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $223.34 | 2024-2025 | Rexulti, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $216.02 | 2021-2025 | Austedo Xr, Austedo Xr |
| Ucb, INC. | $202.73 | 2021-2024 | Rystiggo, Zilbrysq |
| Allergan, INC. | $197.94 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.47 | 2024-2025 | Caplyta |
| Pfizer INC. | $178.26 | 2021-2024 | |
| Jazz Pharmaceuticals INC. | $174.74 | 2021-2022 | |
| Amgen INC. | $165.99 | 2021-2025 | Uplizna |
| Emd Serono, INC. | $141.14 | 2021-2025 | |
| Neurelis, INC. | $138.24 | 2021-2024 | Valtoco |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Lam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.